No description available.

No description available.

No description available.

Infektionen im Bereich der Aorta stellen heute noch eine der gravierendsten Komplikationen der rekonstruktiven Gefäßchirurgie dar. Ziel der vorliegenden Arbeit war es, die Effektivität von kryokonservierten Aortenallografts bei der in situ-Behandlung einer manifesten Infektion im Bereich der Aorta tierexperimentell zu evaluieren. Dessweiteren sollte die Rolle der im Rahmen der Kryokonservierung zum Zwecke der Dekontamination eingesetzten Antibiotika untersucht werden. Zu diesem Zwecke erfolgte im in-vitro Experiment die Untersuchung der Antibiotikakonzentration im Gewebe sowie die der Freisetzungskinetik. Am Modell einer durch Staphylococcus epidermidis RP-62 verursachten Protheseninfektion der infrarenalen Bauchaorta des Hundes konnte eine intrinsische Infektionsresistenz der kryokonservierten Aortenallografts nachgewiesen werden. Jedoch scheint die Antibiotikabehandlung der Allografts für die Optimierung des therapeutischen Effektes essentiell zu sein. Die Ergebnisse der in vivo-Experimente werden durch die in vitro-Untersuchungen, ebenso wie durch die Analyse der eigenen klinischen Ergebnisse und der in der Literatur publizierten Daten belegt. Die vorliegende Arbeit kommt zu dem Schluß, daß die Verwendung von kryokonservierten Allografts das Therapiekonzept der Wahl zur Behandlung von Infektionen im Bereich der Aorta darstellt. / Infections of the aorta remain one of the most dreaded complications in reconstructive vascular surgery. The purposes of this study were to evaluate the efficacy of a cryopreserved aortic allograft to treat an established vascular graft infection by the surgical in situ replacement of the infected segment in an animal model, and to investigate the role of antibiotics to decontaminate the allograft during the cryopreservation process. Furthermore, the tissue concentrations of the antibiotic and the kinetics of desorption were investigated in in vitro experiments. A model of prosthetic graft infection by Staphylococcus epidermidis RP-62 (inserted in the infrarenal aorta) in dogs was developed. By in situ replacement of the infected prosthetic graft with a cryopreserved aortic allograft, this study demonstrated an intrinsic resistance to infection of cryopreserved aortic allografts. However, antibiotic loading of the cryopreserved aortic allografts appeared to be essential to obtain optimal therapeutic effects. The results of these in vivo experiments were supported by the findings of our in vitro studies, as well by analysis of our own clinical results and by clinical data published in the medical literature. We conclude that in situ replacement with a cryopreserved allograft is currently the therapy of choice for an aortic infection.

Glycodelin, a homodimeric glycoprotein belonging to the lipocalin superfamily, is synthesised predominantly by the cells of the reproductive system of certain primates including humans. Of the four different known glycoforms of the molecule, glycodelin A (GdA), secreted by the glandular epithelial cells of the endometrium in response to progesterone, is involved in the immunosuppression of the maternal immune response to the semi-allograft fetus. GdA secretion onsets few days after ovulation. In the absence of fertilization, GdA levels drop, but subsequent to a successful fertilization, the concentrations peak till the 12th week of pregnancy and fall steadily to low levels. The importance of GdA has been implicated in implantation, endometrial receptivity, trophoblast invasion and differentiation, and modulating the functions of almost all immune cells. GdA has profound influence on the activity of T cells. It inhibits the proliferation of T cells, induces apoptosis in activated T cells, inhibits the IL-2 production and leads to skewing of the Th-1/Th-2 balance towards Th-2 type of immune response. Cytotoxic T lymphocytes are more resistant to the induction of apoptosis by GdA, but, it suppresses their cytolytic activity Additionally, GdA induces apoptosis in monocytes and natural killer (NK) cells, inhibits the proliferation of B cells and induces tolerogenic phenotype in dendritic cells. Clinical studies showing that women undergoing recurring spontaneous abortions have low levels of GdA supports its role in prevention of fetus rejection. The immunomodulatory activity of Gd resides in the protein backbone, however, apart from GdA and GdF which have similar oligosaccharide chains, other glycoforms do not possess this activity. Glycosylation seems to dictate the stability, folding and activity of Gd. In absence of glycosylation, the expression of the recombinant Gd is compromised and the protein is improperly folded while over-mannosylation of Gd impairs its immunomodulatory function. Additionally, sialylation seen on the glycan chain regulates the activity. Therefore, in order to obtain adequate amounts of active recombinant Gd (rGd), expression of the protein was attempted in three different systems, insect, yeast and bacteria (Chapter 1). In all of the described systems, the rGd protein was found apoptotically active. The protein expressed in the Sf21 insect cells was demonstrated to be differentially glycosylated compromising the activity. Hence, a genetically modified yeast strain, Pichia pastoris SuperMAN5 was explored for expression. Though presence of a single glycosylated protein species was observed in small-scale cultures, similar to the case of Sf21 cell expression, differentially glycosylated proteins were detected in large-scale fermentation and even the yield was low. Eventually, mutant Gd, modified to increase the stability and aid in proper protein folding, was expressed in E.coli and demonstrated to be able to induce apoptosis in Jurkat cells (T cell leukemia cell line). This active rGd was used for further studies. The immunomodulatory function of GdA during pregnancy protects the semi-allograft fetus from rejection by the maternal immune system. In the process, GdA tweaks the T cell immune response from pro-inflammatory to anti-inflammatory in a specific and localized manner. Allograft rejection seen during mis-match transplantations is basically a pro-inflammatory condition which is mediated by the activation of cellular immune response, NK cell cytotoxicity and antibody-dependent immune response, the same processes that are suppressed for a successful pregnancy. Chapter 2 discusses whether it is feasible to use Gd to prevent allograft rejection. Killing of target graft cells by the cytotoxic T lymphocytes (CTLs) predominantly presides acute graft rejection. GdA treatment has been shown to suppress the cytotoxicity of in vitro generated CTLs. On this basis, the earlier study was translated to in vivo conditions by establishing an allograft nude mouse model. The tumor rejection mediated by the action of in vitro generated cytotoxic alloactivated PBMCs in the nude mouse imitated the allograft rejection. A heterogenous population of immune cells with the predominance of CTLs was chosen to accommodate a more interactive immune response in the tumor microenvironment and enabled the study of other cells which may contribute to the rejection. Reactivation and proliferation of CD4+ and CD8+ T cells following their infiltration in the tumor validated our hypothesis. On treatment with rGd, the cytotoxicity of the alloactivated PBMCs was suppressed, thereby inhibiting the tumor rejection in the nude mouse. Real time PCR analysis showed that rGd treatment was able to affect the functions of the immune cells in vivo. It decreased the T cell population most probably by inducing apoptosis. As expected, the reduction was more prominent in case of CD4+ T cells than CD8+ T cells. The their expression of key molecules responsible for the cytotoxicity such as IL-2, granzyme B and EOMES, was observed to be downregulated by rGd. Concomitantly, decreased levels of pro-inflammatory cytokines, TNFα and IL-6 were also seen. Expression of Foxp3, marker for regulatory T cells, was upregulated in the tumor infiltrating immune cells suggesting an expansion of the concerned population upon rGd treatment. Overall, rGd seems to suppress the cellular immune response to the tumor by modulating the T cell population and their functions. Since, T cell-dependent immune response is central to allograft rejection, the ability of rGd to regulate it could be of therapeutic use in the management of allograft rejection. NK cells are essential for the maintenance of pregnancy, evident from their abundance (70% of total leukocytes) at the first trimester decidua. The third chapter focuses on how Gd regulates the NK cell function. The cytokine production from CD56bright subset of NK cells and their interaction with the HLA antigens expressed by the trophoblast cells helps in creating a favourable environment for the growth of the fetus. It is important to note that the NK cell population present in the decidua exclusively express Gd, implicating a role of Gd in their differentiation from the peripheral CD56bright cells. However, an increased number of CD56dimCD16+ cells in the peripheral blood dictates a negative outcome for the pregnancy. The study, presented in Chapter 3, demonstrated that rGd treatment induces caspase-dependent apoptosis in the activated CD56dimCD16+ cells and reduces their cytotoxicity by downregulating granzyme B and IFNγ production. Similar effect of rGd is also seen on the NKT cells characterised as CD3+CD56dimCD16-. Furthermore, in YT-Indy cells, an activated NK cell line, it was shown that the induction of apoptosis by rGd involves Ca2+ signalling which could explain why Gd affects activated immune cells only. This study therefore reinforces the role of Gd in modulating the NK cell activity during pregnancy. Cytotoxicity of NK and NKT cells also plays an important role during allograft rejection. Decrease in the mRNA levels of CD56 upon rGd treatment in the allograft mouse model indicates that the effect of Gd on NK cells observed in cell culture system can be translated to in vivo conditions. In conclusion, suppression of the cellular immune response and NK cell mediated cytotoxicity by rGd could potentiate its’ probable use in the management of allograft rejection. .

No description available.

Einleitung: Die Implantation kryokonservierter allogener Aortenklappen stellt heutzutage eine effektive operative Technik dar, um in schweren Fällen einer floriden Aortenklappenendokarditis exzellente postoperative Ergebnisse zu erzielen. Diese Studie demonstriert die Langzeitergebnisse im Deutschen Herzzentrum Berlin über einen Zeitraum von 17 Jahren. Material und Methoden: Zwischen dem 1.Januar 1987 und 31.Dezember 2003 wurden bei 203 Patienten mit florider Aortenklappenendokarditis kryokonservierte Aortenklappenallografts implantiert (in subkoronarer Implantationstechnik n=107 und durch totalen Aortenwurzelersatz n=96). Das mittlere Alter der Patienten betrug 51,3 Jahre (2-82 Jahre). Darunter waren 42 Frauen und 161 Männer. 161 Patienten zeigten präoperativ eine anuläre Aortenwurzelabszeßbildung. Ergebnisse: Die 30-Tage-Mortalität (mit Anulusabszeß) betrug insgesamt 21,1% (23,6%): bei nativer Aortenklappenendokarditis 14,9% (17,5%) und bei Prothesen-endokarditis 29,2% (29,6%). Nach 17 Jahren waren 70,4+3,6% und 78,6+6,3% (p=0,24) der Patienten mit und ohne präoperativem Anulusabszeß am Leben. Bei 12 Patienten mit Anulusabszeß trat eine Allograft-Re-Infektion auf, die aktualisierte Freiheit von Reinfektion betrug 91,6+2,4% nach 17 Jahren. Insgesamt wurden 37 Patienten reoperiert, die aktualisierte Freiheit von Reoperation betrug 75,0+3,7% nach 17 Jahren. Die aktualisierte Freiheit von Explantation der Allografts wegen Strukturalteration betrug bei den Patienten mit Anulusabszeß nach 17 Jahren 96,0+2,0%. Thrombembolische Ereignisse traten nicht auf. Die Univarianzanalyse identifizierte die Allograft-Re-Infektion (p=0,0001) und zu klein bemessene Allografts (p=0,001) als Risikofaktoren für eine Reoperation sowohl bei nativer als auch Prothesenendokarditis. Schlußfolgerung: Aortenklappenallografts zeigen bei florider Aortenklappenendokarditis mit Anulusabszeß exzellente Langzeitresultate. Die 30-Tage–Mortalität wird hinsichtlich der Schwere der Erkrankung akzeptiert und Re-Infektionen sind selten. Zu klein bemessene Allografts und Re-Infektionen sind Risikofaktoren für Reoperationen. / Objective: Cryopreserved aortic valve homografts have become an accepted valve substitute in acute aortic valve endocarditis, but long-term studies of valve function are largely unavailable. This survey represents our observations over a period of 17 years. Material and methods: Between February 9, 1987 and October 30, 2003, 203 patients with infective aortic valve endocarditis underwent allograft replacement of the aortic valve (free-hand subcoronary technique, n=107 and root replacement, n=96). The patients’ age ranged between 2 and 82 years with a mean age of 51.3 years. The survey included 42 females and 161 males. 161 had infected aortic root with ring abscesses. Results: The hospital mortality of patients with native and prosthetic endocarditis complicated by periannular abscess was 14.9% (17.5%) and 29.2 % (29.6%) respectively making an overall hospital mortality of 21.2% (23.6%). 17 years patient survival in patients with and without periannular abscess was 70.4+3.6% and 78.6+6.3% (p=0,24) respectively. There were 12 events of recurrent endocarditis in patients with periannular abscess, giving an actuarial freedom of 91.6+2.4% at 17 years. Reoperation was performed in 37 patients for a variety of reasons, and overall freedom from reoperation was 75.0+3.7% at 17 years. Freedom from explantation for structural valve deterioration was 96.0+2.0% at 17 years for patients with periannular abcess. No thrombembolic event was evident. Univariable analysis identified recurrent endocarditis (p=0.0001) and undersized allograft (p=0.001) as risk factors for reoperation for both native and prosthetic aortic valve endocarditis. No risk factors for hospital mortality were found. Conclusion: Aortic allograft offers an excellent long-term clinical result in patients with infective aortic valve endocarditis with associated periannular abscess. Operative mortality is acceptable based on the severity of aortic pathology, with low evidence of recurrent endocarditis and no thrombembolic events. Undersized allograft and recurrent infection are risk factors for reoperation.

Optimale Konservierungsmethoden sind erforderlich, um die bedarfsgerechte Verfügbarkeit kardiovaskulärer Transplantate für den Ersatz geschädigter Gewebe (Herzklappen oder Gefäße) zu garantieren. Die konventionelle Kryokonservierung (engl.: Conventional Frozen Cryopreservation, CFC) ist derzeit der Standard zur Konservierung kardiovaskulärer Allografts. Jedoch limitieren Immunreaktionen deren Langzeitfunktionalität. Die Alternative der eisfreien Kryokonservierung (engl.: Ice-free Cryopreservation, IFC) wurde kürzlich entwickelt. In der Arbeit wurde die Reaktion des humanen Immunsystems auf allogene kardiovaskuläre Gewebe nach Anwendung unterschiedlicher Konservierungsmethoden umfänglich charakterisiert. Zusätzlich wurde Glutaraldehyd (GA)-fixiertes Gewebe untersucht, um die Ergebnisse in den Gesamtkontext der Gewebekonservierung einzuordnen. Die Analyse des konservierten humanen Aortengewebes, welches als Modellmaterial diente, ergab, dass die Gewebestruktur nach IFC erhalten blieb, jedoch die metabolische Aktivität sowie Apoptose und Nekrose des Gewebes durch IFC reduziert wurde. Dies spiegelte sich auch in der verminderten Freisetzung von Zytokinen aus IFC-Gewebe wider. Funktionelle In-vitro-Tests zeigten deutlich, dass Immunzellen verstärkt in Richtung der löslichen Faktoren aus CFC- und GA-fixiertem Gewebe, jedoch nicht aus IFC-Gewebe migrieren. In Kokulturen der Makrophagen auf dem Aortengewebe konnte ausschließlich bei Makrophagen, welche auf GA-fixiertem Gewebe kultiviert wurden, eine Polarisation zum M1-Phänotyp festgestellt werden. Weiterhin zeigte sich, dass lediglich Faktoren des CFC-Gewebes in der Lage waren, die Aktivierung und Proliferation von T-Zellen zu verstärken. Insgesamt belegen diese Daten detailliert, dass IFC die Eigenschaften des Gewebes selektiv moduliert und dadurch eine verringerte Aktivierung des Immunsystems stattfindet. Die Ergebnisse verdeutlichen, dass IFC eine aussichtsreiche Strategie zur verbesserten Konservierung darstellt. / Optimal preservation methods are needed, to ensure constant availability of biological matrices for the replacement of damaged cardiovascular structures (heart valves or vessels). Conventional frozen cryopreservation (CFC) is currently the gold standard for cardiovascular allograft preservation. However, inflammation and structural deterioration limit transplant durability. The recently developed method of Ice-free cryopreservation (IFC) might be a superior method. The aim of this study was to characterize the reaction of the human immune system to allogeneic cardiovascular tissues after different cryopreservation methods. Regarding some aspects, the cryopreservation was compared to glutaraldehyde (GA) fixation, which is another common tissue preservation method. Human aortic tissue served as a proof-of-principle material for heart valves and vascular allografts. First, the histological and metabolic features of the differently preserved aortic tissues were analyzed. Tissues preserved by IFC exhibited typical architecture but significantly lower metabolic activity and the absence of necrotic or apoptotic cells. The reduced release of cytokines from IFC-tissue reflected these latter observations. In functional in-vitro-assays it was shown that migration of immune cells was significantly enhanced by soluble factors from CFC and GA-fixed tissue, but not by factors from IFC-tissue. In co-cultures of macrophages on aortic tissue, none of the preserved tissue induced activation. Exclusively GA-fixed tissue triggered the polarization of macrophages towards a M1-phenotype. Moreover, cues from only CFC-tissue but not IFC-tissue amplified T cell activation and proliferation. In conclusion, IFC selectively modulates the characteristics of tissues resulting in an attenuated activation of the human immune system. Therefore, IFC treatment is a promising strategy for improved tissue preservation and storage of cardiovascular allografts for clinical use.

Introduction: Heart failure remains a major public health problem, with recent estimates indicating that end-stage heart failure with two-year mortality rates of 70-80% affects over 60,000 patients in the US each year. Medical management can be used but success declines for patients with end stage heart failure. Although cardiac transplantation is optimal, less than 2500 cardiac transplants are performed annually due to the severely limited supply of donor organs. Mechanical circulatory support (MCS) devices are now routinely used to bridge patients with end-stage heart failure who become critically ill until a donor heart is available. The use of stem cell therapy to treat heart failure has been gaining significant ground in recent years, specifically due to its regenerative properties, and both animal and human models have shown significant improvements in ventricular mass, ejection fraction, vascularization, wall thickness, and infarct size reduction. Using the patients' HeartWare HVAD device diagnostics, we were able to acquire our response variable; pulsatility. Pulsatility is a variable measure of the differential between minimum and maximum flow and is dependent on device motor speed, power, current, and fluid viscosity. This measurement is important as it relates to the contractility of the heart and could potentially be used as an end point in determining when a patient is healthy enough to have their HVAD explanted. We set out to develop a low cost and effective predictive model to determine amniotic mesenchymal stem cell's ability to repair compromised cardiac tissue of patients using the Total Artificial Heart (TAH) and Donovan Mock Circulation Tank (DMC). Methods: Predictive modelling was performed using the TAH and DMC. The system was set to a range from critical heart failure to a normal operating conditions through the variation of preload, afterload, and ventricular drive pressures with the intent of comparing the results to our patient population. Patients (n=7, 3 dilated, 4 ischemic) received intravenous and intra-myocardial injections of a heterogeneous amniotic mesenchymal stem cells mixture and liquid matrix (MSCs+LM) at HVAD implant. Groups were analyzed based on treatment; control (HVAD only, n=7) versus stem cells (HVAD + MSCs+LM). HeartWare log files were acquired from patients' devices and analyzed in SAS and Matlab. Results from the patient study were compared to the predictive model to determine levels of stem cell response. Results: Pulsatility was found to increase with left drive pressure and afterload. Lower drive pressures resulted in a drop off in pulsatility at higher afterloads while higher drive pressures were able to compensate for any afterload. Pulsatility also increased with preload but lower drive pressures were unable to fully eject at the highest preloads, resulting in a reduced pulsatility. We observed the effects of the stem cell injections on pulsatility and found that patients receiving therapy demonstrated statistically significant increases in pulsatility at 15-20 (p=.0487), 25-30 (p=.0131), 35-40 (p=.0333), and 75-80 (p=0.0476) days post implant. At minimum, when comparing the patient results to the in vitro model, the therapy resulted in a progression from end stage HF conditions to medium cardiac function conditions. At maximum, the therapy resulted in a progression from end stage HF to normal healthy operating cardiac function. Conclusions: Stem cells demonstrated a significantly increased rate of change in pulsatility within the first 40 days and at 80 days post implant when compared to control. They also demonstrated progression from end stage HF to normal healthy cardiac function at two time periods (Days 40, 90). These results justify expansion of the study to encompass a larger patient population to verify the results of the in vitro model to predict cardiac regeneration with multiple functional status indicators.

Für Patienten mit fortgeschrittener Herzinsuffizienz ist die Herztransplantation die einzige kurative Therapieoption. Die akute Abstoßungsreaktion ist ein entscheidender Faktor der Mortalität nach Transplantation. Zur Früherkennung einer Abstoßungsreaktion gilt nach wie vor die Endomyokardbiopsie als Goldstandard. Diese stellt jedoch ein invasives Verfahren mit seltenen, aber potentiell schwerwiegenden Komplikationen dar. In der vorliegenden Studie wurde die diagnostische Wertigkeit der kardialen Magnetresonanztomographie zur Detektion der Abstoßungsreaktion nach Herztransplantation untersucht. Als Referenz diente die Myokardbiopsie mit histologischer Beurteilung nach dem Schema der International Society of Heart and Lung Transplantation (ISHLT). Insbesondere bei Kombination mehrerer Parameter konnte ein hoher negativ prädiktiver Wert zum Ausschluss einer akuten Abstoßungsreaktion erzielt werden. Dagegen waren Spezifität und positiv prädiktiver Wert zu gering, um eine Therapie-Änderung alleine auf Basis eines positiven MRT-Befundes zu rechtfertigen.